CY1106676T1 - Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως - Google Patents

Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως

Info

Publication number
CY1106676T1
CY1106676T1 CY20071100841T CY071100841T CY1106676T1 CY 1106676 T1 CY1106676 T1 CY 1106676T1 CY 20071100841 T CY20071100841 T CY 20071100841T CY 071100841 T CY071100841 T CY 071100841T CY 1106676 T1 CY1106676 T1 CY 1106676T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
delivery
improving
therapeutic nucleic
recipient
Prior art date
Application number
CY20071100841T
Other languages
Greek (el)
English (en)
Inventor
James G. Barsoum
Michael Parr
Stephen E. Fawell
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of CY1106676T1 publication Critical patent/CY1106676T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20071100841T 2001-01-22 2007-06-25 Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως CY1106676T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26341601P 2001-01-22 2001-01-22
PCT/US2002/001797 WO2002056918A2 (en) 2001-01-22 2002-01-22 Method of enhancing delivery of a therapeutic nucleic acid

Publications (1)

Publication Number Publication Date
CY1106676T1 true CY1106676T1 (el) 2012-05-23

Family

ID=23001688

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100841T CY1106676T1 (el) 2001-01-22 2007-06-25 Μεθοδος βελτιωσεως της διανομης ενος θεραπευτικου νουκλεϊνικου οξεως

Country Status (13)

Country Link
US (1) US7534424B2 (enExample)
EP (1) EP1363676B1 (enExample)
JP (1) JP2005502585A (enExample)
AT (1) ATE357935T1 (enExample)
AU (1) AU2002237910B2 (enExample)
CA (1) CA2435443A1 (enExample)
CY (1) CY1106676T1 (enExample)
DE (1) DE60219142T2 (enExample)
DK (1) DK1363676T3 (enExample)
ES (1) ES2283524T3 (enExample)
NZ (1) NZ527645A (enExample)
PT (1) PT1363676E (enExample)
WO (1) WO2002056918A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
WO2011074564A1 (ja) * 2009-12-15 2011-06-23 タカラバイオ株式会社 アデノウイルスベクターの製造方法
US20140141065A1 (en) * 2012-11-19 2014-05-22 Discovery Genomics, Inc. Method to achieve extended expression of dna infused into liver

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EA003256B1 (ru) * 1997-08-29 2003-02-27 Байоджен, Инк. СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ IN VIVO ПРИ ПОМОЩИ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ β-ИНТЕРФЕРОН
US20010031741A1 (en) * 2000-02-17 2001-10-18 Robin Ziegler Methods for treatment of lysosomal storage diseases

Also Published As

Publication number Publication date
PT1363676E (pt) 2007-06-22
US20040086486A1 (en) 2004-05-06
ES2283524T3 (es) 2007-11-01
AU2002237910B2 (en) 2007-01-25
DE60219142T2 (de) 2007-12-13
AU2002237910C1 (en) 2002-07-30
DK1363676T3 (da) 2007-07-23
EP1363676A2 (en) 2003-11-26
WO2002056918A3 (en) 2002-11-14
EP1363676B1 (en) 2007-03-28
JP2005502585A (ja) 2005-01-27
US7534424B2 (en) 2009-05-19
NZ527645A (en) 2008-10-31
WO2002056918B1 (en) 2004-04-08
CA2435443A1 (en) 2002-07-25
DE60219142D1 (de) 2007-05-10
ATE357935T1 (de) 2007-04-15
WO2002056918A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BR112022025653A2 (pt) Vacina autoamplificante de rna sars-cov-2
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
ATE543873T1 (de) Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
CY1106752T1 (el) Διϋδροπτεριδινονες, μεθοδος για την παραγωγη τους και χρηση τους ως φαρμακων
CY1112585T1 (el) Hla-dr-προσδενομενο πεπτιδιο αντιγονου προερχομενο απο wt1
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
ATE395930T1 (de) Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
CY1106564T1 (el) Πολυπεπτιδια δυναμενα αποσπασης μιας ανοσιακης αντιδρασης εναντι του καρκινου
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
ATE509949T1 (de) Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen
GT200300154A (es) Aldehidos de polietilenglicol
CY1113871T1 (el) Διαδικασια παρασκευης γκαμπαπεντινης
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα